← Back to headlines
UBS Strongly Resets Eli Lilly Stock Target
UBS has significantly adjusted its stock target for Eli Lilly, indicating a strong re-evaluation of the pharmaceutical company's market prospects. This reset reflects new analysis or market conditions impacting the stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
